Advances and Innovations in Wound Repair and Regeneration

A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Regenerative Engineering".

Deadline for manuscript submissions: 31 August 2025 | Viewed by 974

Special Issue Editor


E-Mail Website
Guest Editor
1. Skin Bioengineering Laboratory, Victorian Adult Burns Service, Alfred Health, 89 Commercial Road, Melbourne, VIC, Australia
2. Department of Surgery, Monash University, 99 Commercial Road, Melbourne, VIC 3004, Australia
Interests: skin tissue engineering; skin grafting; wound repair; cell and tissue therapies; adult stem cells

Special Issue Information

Dear Colleagues,

Despite many years of research, repairing wounds through regeneration without scarring in a timely fashion remains an unmet clinical need. Skin grafting remains the gold standard for closing large wounds but has many inherent limitations. Most importantly, skin grafts lack appendages, including hair follicles, and undergo contracture over time. Even in smaller wounds that heal spontaneously within three weeks, the tissue is replaced with scar tissue, resulting in cosmetic and physiological long-term consequences.

The aim of this Special Issue is to showcase the latest novel approaches in cell therapy, biomaterials, small molecules, nanoparticles, organoids, and animal models for wound regeneration. Multi-disciplinary technological innovations such as 3D printing and automation will also be included. Reviews and clinical studies are also welcome.

Topics of interest for this Special Issue include, but are not limited to, the following:

  • Small molecules and nanoparticles for wound repair
  • Anti-fibrotic drugs
  • Engineered skin grafts
  • Dermal substitutes
  • Biological wound dressings
  • Three-dimensional skin printing
  • Animal models

Dr. Shiva Akbarzadeh
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • engineered skin graft
  • three-dimensional skin printing
  • skin grafting in animal models
  • dermal substitutes

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 672 KiB  
Review
Towards Extracellular Vesicles in the Treatment of Epidermolysis Bullosa
by Aaron Gabriel W. Sandoval and Evangelos V. Badiavas
Bioengineering 2025, 12(6), 574; https://doi.org/10.3390/bioengineering12060574 - 27 May 2025
Viewed by 373
Abstract
Epidermolysis bullosa (EB) is a debilitating genetic skin disorder characterized by extreme fragility, chronic wounds, and severe complications, particularly in its most severe form, recessive dystrophic EB (RDEB). Current treatments focus on symptomatic relief through wound care and pain management, with recent FDA [...] Read more.
Epidermolysis bullosa (EB) is a debilitating genetic skin disorder characterized by extreme fragility, chronic wounds, and severe complications, particularly in its most severe form, recessive dystrophic EB (RDEB). Current treatments focus on symptomatic relief through wound care and pain management, with recent FDA approvals of Vyjuvek and Filsuvez providing new but limited therapeutic options. However, emerging research highlights the potential of extracellular vesicles (EVs) derived from mesenchymal stem cells as a promising approach to address both the symptoms and underlying pathology of EB. EVs function as carriers of bioactive molecules, modulating inflammation, promoting tissue regeneration, and even delivering functional type VII collagen to RDEB patient cells. Unlike whole-cell therapies, EVs are non-immunogenic, have greater stability, and avoid risks such as graft-versus-host disease or tumorigenic transformation. Additionally, EVs offer diverse administration routes, including topical application, local injection, and intravenous delivery, which could extend their therapeutic reach beyond skin lesions to systemic manifestations of EB. However, challenges remain, including standardization of EV production, scalability, and ensuring consistent therapeutic potency. Despite these hurdles, EV-based therapies represent a transformative step toward addressing the complex pathology of EB, with the potential to improve wound healing, reduce fibrosis, and enhance patient quality of life. Full article
(This article belongs to the Special Issue Advances and Innovations in Wound Repair and Regeneration)
Show Figures

Figure 1

Back to TopTop